Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Targeting the Hippo Pathway in Melanoma

Version 1 : Received: 8 April 2024 / Approved: 8 April 2024 / Online: 9 April 2024 (08:52:48 CEST)

How to cite: Kazimierczak, U.; Przybyła, A.; Smielowska, M.; Kolenda, T.; Mackiewicz, A. Targeting the Hippo Pathway in Melanoma. Preprints 2024, 2024040621. https://doi.org/10.20944/preprints202404.0621.v1 Kazimierczak, U.; Przybyła, A.; Smielowska, M.; Kolenda, T.; Mackiewicz, A. Targeting the Hippo Pathway in Melanoma. Preprints 2024, 2024040621. https://doi.org/10.20944/preprints202404.0621.v1

Abstract

Melanoma is the most aggressive form of skin cancer. In the advanced stage of development it is resistant to currently available therapeutic modalities. Increased invasiveness and metastatic potential depend on a number of proteins involved in various signal transduction pathways. Hippo signaling plays an important role in malignant transformation. Dysfunctions of the Hippo pathway initiate the expression of tumor growth factors and is associated with tumor growth and metastasis formation. This review summarizes the recent achievements in studying the role of the Hippo pathway in melanoma pathogenesis and points to the potential specific targets for anti-melanoma therapy.

Keywords

Hippo signaling; melanoma; therapy

Subject

Biology and Life Sciences, Cell and Developmental Biology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.